您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > PD168393(PD-168393)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PD168393(PD-168393)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PD168393(PD-168393)图片
CAS NO:194423-15-9
规格:≥98%
包装与价格:
包装价格(元)
1mg电议
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)369.22
FormulaC17H13BrN4O
CAS No.194423-15-9
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 74 mg/mL (200.4 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)30% PEG400+0.5% Tween80+5% propylene glycol: 30mg/mL
SynonymsPD 168393; PD-168393; PD168393; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline

InChi Key: HTUBKQUPEREOGA-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)

SMILES Code: C=CC(NC1=CC2=C(NC3=CC=CC(Br)=C3)N=CN=C2C=C1)=O

实验参考方法
In Vitro

In vitro activity: PD 168393 is docked into the ATP binding pocket of EGFR TK. PD168393 completely suppresses EGF-dependent receptor autophosphorylation in A431 cells during continuous exposure, with continous suppression even after 8 hr in compound-free medium. PD168393 inhibits heregulin-induced tyrosine phosphorylation in MDA-MB-453 cells with IC50 of 5.7 nM. PD168393 is inactive against insulin, PDGF and basic FGFR TKs as well as PKC. PD168393 inhibits EGF-mediated tyrosine phosphorylation in HS-27 human fibroblasts with IC50 of 1-6 nM but has little effect on FGF- or PDGF-mediated tyrosine phosphorylation. PD168393 shows rapid and potent inhibition of Her2-induced tyrosine phosphorylation with IC50 of ~100 nM in 3T3-Her2 cells. D168393 also inhibits phosphorylation of PLCγ1/Stat1/Dok1/δ-catenin in 3T3-Her2 cells, except for Fyb.


Kinase Assay: PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFR IC 50: 0.7 nM (1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with>9-fold greater potency than PD 174265. (2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes. (3) PD168393 completely inhibits AKT and ERK phosphorylation at concentrations as low as 0.03 umol/L. (4) PD168393 could induce apoptosis and inhibit cell growth in ErbB2 positive lung and breast cancer cell lines. (5) PD168393 disrupted MEK1/p44/42 ERK signaling in HaCaT cells as determined by inhibition of phospho-p44/42 ERK.


Cell Assay: (1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with>9-fold greater potency than PD 174265. (2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes. (3) PD168393 completely inhibits AKT and ERK phosphorylation at concentrations as low as 0.03 umol/L. (4) PD168393 could induce apoptosis and inhibit cell growth in ErbB2 positive lung and breast cancer cell lines.

In VivoPD 168393 produces tumor growth inhibition of 115% in A431 human epidermoid carcinoma xenograft in nude mice, with 50% reduced phosphotyrosine content of EGFR. PD 168393 also shows a low plasma concentration.
Animal modelAthymic nude mice with A431 human epidermoid carcinoma
Formulation & DosageFormulated in 4% dimethylacetamide in aqueous 50 mM sodium lactate buffer (pH 4); 58 mg/kg; i.p.
ReferencesProc Natl Acad Sci U S A. 1998 Sep 29; 95(20): 12022–12027; Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9773-8.